This company listing is no longer active
VIFN Stock Overview
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Vifor Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF166.15 |
| 52 Week High | CHF197.20 |
| 52 Week Low | CHF157.75 |
| Beta | 1.04 |
| 1 Month Change | -1.37% |
| 3 Month Change | -5.33% |
| 1 Year Change | 1.93% |
| 3 Year Change | -7.67% |
| 5 Year Change | 33.03% |
| Change since IPO | 1,057.84% |
Recent News & Updates
Recent updates
I Ran A Stock Scan For Earnings Growth And Vifor Pharma (VTX:VIFN) Passed With Ease
Dec 14
Is Vifor Pharma (VTX:VIFN) Using Too Much Debt?
Nov 24Here's Why We Think Vifor Pharma (VTX:VIFN) Is Well Worth Watching
Sep 03Is Vifor Pharma (VTX:VIFN) A Risky Investment?
Aug 17Do Investors Have Good Reason To Be Wary Of Vifor Pharma AG's (VTX:VIFN) 1.6% Dividend Yield?
May 10Vifor Pharma (VTX:VIFN) Seems To Use Debt Quite Sensibly
Mar 30Could The Vifor Pharma AG (VTX:VIFN) Ownership Structure Tell Us Something Useful?
Mar 10How Much Did Vifor Pharma's(VTX:VIFN) Shareholders Earn From Share Price Movements Over The Last Year?
Feb 19Key Things To Consider Before Buying Vifor Pharma AG (VTX:VIFN) For Its Dividend
Jan 15
Vifor Pharma AG's (VTX:VIFN) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Dec 24Is Vifor Pharma (VTX:VIFN) Using Too Much Debt?
Dec 01Getting In Cheap On Vifor Pharma AG (VTX:VIFN) Might Be Difficult
Jul 17Shareholder Returns
| VIFN | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 0.4% | -1.3% | -2.1% |
| 1Y | 1.9% | -12.4% | -3.6% |
Return vs Industry: VIFN exceeded the Swiss Pharmaceuticals industry which returned -0.8% over the past year.
Return vs Market: VIFN exceeded the Swiss Market which returned -19% over the past year.
Price Volatility
| VIFN volatility | |
|---|---|
| VIFN Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 3.0% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: VIFN has not had significant price volatility in the past 3 months.
Volatility Over Time: VIFN's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1872 | 2,200 | n/a | www.viforpharma.com |
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD) It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis.
Vifor Pharma AG Fundamentals Summary
| VIFN fundamental statistics | |
|---|---|
| Market cap | CHF10.78b |
| Earnings (TTM) | CHF146.60m |
| Revenue (TTM) | CHF1.81b |
73.5x
P/E Ratio5.9x
P/S RatioIs VIFN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIFN income statement (TTM) | |
|---|---|
| Revenue | CHF1.81b |
| Cost of Revenue | CHF671.80m |
| Gross Profit | CHF1.14b |
| Other Expenses | CHF993.70m |
| Earnings | CHF146.60m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.26 |
| Gross Margin | 62.93% |
| Net Profit Margin | 8.09% |
| Debt/Equity Ratio | 13.6% |
How did VIFN perform over the long term?
See historical performance and comparison